On May 27, 2024, Fresenius Kabi announced the FDA acceptance of its aBLA for FKS518 (denosumab), a proposed biosimilar of Amgen’s Prolia^® / Xgeva^® (denosumab).  This is the third publicly announced aBLA for a Prolia^® / Xgeva^® biosimilar; Sandoz’s Jubbonti^® / Wyost^® (denosumab-bddz) was approved as interchangeable on March 5, 2024, and Celltrion’s CT-P41 (denosumab) aBLA is pending (submitted to the FDA in November 2023).

At the end of April 2024, Amgen and Sandoz settled a BPCIA litigation related to a denosumab biosimilar (Case No. 1:23-cv-02406 (D.N.J.)), agreeing to an injunction until February 19, 2025, with a market entry date for Jubbonti^® / Wyost^® by May 31, 2025, or earlier under certain undisclosed circumstances (previously reported: Amgen and Sandoz Settle Prolia^® / Xgeva^® Biosimilar Litigation).

According to Bloomberg, combined U.S. sales for Prolia^® ($2.7 B) and Xgeva^® ($1.5B) accounted for more than 15% of Amgen’s 2023 total revenue.

_____________________________________________________

The authors would like to thank April Breyer Menon for her contributions to this article.